%0 Journal Article
%A Genescà, E
%A Lazarenkov, A
%A Morgades, M
%A Berbis, G
%A Ruíz-Xivillé, N
%A Gómez-Marzo, P
%A Ribera, J
%A Juncà, J
%A González-Pérez, A
%A Mercadal, S
%A Guardia, R
%A Artola, M T
%A Moreno, M J
%A Martínez-López, J
%A Zamora, L
%A Barba, P
%A Gil, C
%A Tormo, M
%A Cladera, A
%A Novo, A
%A Pratcorona, M
%A Nomdedeu, J
%A González-Campos, J
%A Almeida, M
%A Cervera, J
%A Montesinos, P
%A Batlle, M
%A Vives, S
%A Esteve, J
%A Feliu, E
%A Solé, F
%A Orfao, A
%A Ribera, J M
%T Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia.
%D 2018
%U http://hdl.handle.net/10668/12748
%X Recurrent deletions of the CDKN2A/ARF/CDKN2B genes encoded at chromosome 9p21 have been described in both pediatric and adult acute lymphoblastic leukemia (ALL), but their prognostic value remains controversial, with limited data on adult T-ALL. Here, we investigated the presence of homozygous and heterozygous deletions of the CDKN2A/ARF and CDKN2B genes in 64 adult T-ALL patients enrolled in two consecutive trials from the Spanish PETHEMA group. Alterations in CDKN2A/ARF/CDKN2B were detected in 35/64 patients (55%). Most of them consisted of 9p21 losses involving homozygous deletions of the CDKNA/ARF gene (26/64), as confirmed by single nucleotide polymorphism (SNP) arrays and interphase fluorescence in situ hybridization (iFISH). Deletions involving the CDKN2A/ARF/CDKN2B locus correlated with a higher frequency of cortical T cell phenotype and a better clearance of minimal residual disease (MRD) after induction therapy. Moreover, the combination of an altered copy-number-value (CNV) involving the CDKN2A/ARF/CDKN2B gene locus and undetectable MRD (≤ 0.01%) values allowed the identification of a subset of T-ALL with better overall survival in the absence of hematopoietic stem cell transplantation.
%K CDKN2A/ARF
%K CDKN2B
%K MRD
%K Prognosis
%K T-ALL
%~